deleted in breast cancer 1; adipose tissue; obesity; insulin sensitivity; adipogenesis ADIPOSE TISSUE PLAYS A CENTRAL ROLE in the management of systemic energy stores (storing and mobilizing triglycerides) as well as in regulating whole body metabolism and glucose homeostasis (7) . Obesity-associated adipose tissue dysfunction is defined as an impaired capacity for triglyceride storage associated with mitochondrial dysfunction, increased oxidative and endoplasmic reticulum stress, and systemic inflammation (1, 7, 8, 15, 16) . All of these processes finally lead to insulin resistance and obesity-associated metabolic disturbances.
Deleted in breast cancer 1 (DBC1; CCAR2, p30 DBC, or KIAA1967), initially cloned from a region (8p21) homozygously deleted in breast cancers, is a pleiotropic nuclear protein that interacts and modulates the activity of several nuclear receptors (2) and enzymes involved in epigenetic processes (2, 3, 9, 17) . Genetic deletion of Dbc1 in mice led to enhanced browning of white adipose tissue (13) , suggesting a possible role of DBC1 in white adipogenesis. However, in a recent study, Escande et al. (4) showed that DBC1 knockout (KO) in mice resulted in fat accumulation, increasing adipogenesis and insulin signaling in parallel with the reduction of fasting glucose and free fatty acids and suggesting that the deletion of DBC1 promotes a "healthy obese" phenotype, preventing adipose tissue senescence and inflammation (5) . Furthermore, high-fat diet-induced obesity is known to promote DBC1 and sirtuin 1 (SIRT1) protein interaction, leading to a significant decrease in sirtuin activity in adipose tissue (4) . Previous studies have shown that sirtuin activity attenuates high-fat diet-induced adipose tissue inflammation (6, 16) .
To the best of our knowledge, no previous studies examined DBC1 gene expression in human adipose tissue or in association with obesity. We also found no studies exploring the effects of DBC1 downregulation (not total genetic depletion) during adipocyte differentiation. Thus, we aimed to investigate DBC1 mRNA levels in association with obesity and markers of adipogenesis in human adipose tissue and isolated human adipocytes and the possible role of DBC1 knockdown on 3T3-L1 adipocyte differentiation.
MATERIALS AND METHODS

Patients' recruitment and human adipose tissue sample handling.
In cohort 1, a group of 206 adipose tissue samples [101 subcutaneous abdominal and 105 omental abdominal (visceral) from the same location] were obtained during open elective surgery [cholecystectomy (n ϭ 10), surgery of abdominal hernia (n ϭ 15), and gastric by-pass surgery (n ϭ 80)] from participants with a body mass index (BMI) between 20 and 68 kg/m 2 . Among the obese type 2 diabetic patients, the majority of patients were recently diagnosed. Only two subjects were treated with metformin, one with glitazones and one with insulin. In a second cohort (cohort 2) of morbidly obese (BMI Ͼ40 kg/m 2 ) subjects with different degrees of insulin action (measured using euglycemic clamp), 47 subcutaneous and 42 visceral adipose tissue samples were studied. For both cohorts, all participants were invited to participate at the Endocrinology Service of the Hospital of Girona "Dr. Josep Trueta" (Girona, Spain). All subjects were of Caucasian origin and reported that their body weight had been stable for Ն3 mo before the study. Liver and renal diseases were excluded specifically by biochemical workup, measuring biomarkers of liver injury like aspartate aminotransferase, alanine aminotransferase, and ␥-glutamyl transpeptidase. Those subjects with values that were more than twice the upper limit of normal were excluded. All subjects gave written informed consent, which was validated and approved by the Ethics Committee of the Hospital of Girona "Dr.
Josep Trueta" (Comitè d'Ètica d'Investigació Clínica), after the purpose of the study was explained to them. Samples of adipose tissue were immediately transported to the laboratory (5-10 min). The handling of tissue was carried out under strictly aseptic conditions. Adipose tissue samples were washed in PBS, cut off with forceps and scalpel into small pieces (100 mg), and immediately flash-frozen in liquid nitrogen before storage at Ϫ80°C. The isolation of adipocyte and stromal vascular fraction (SVF) cells was performed from six SAT and eight VAT nonfrozen adipose tissue samples. These samples were washed three to four times with phosphate-buffered saline (PBS) and suspended in an equal volume of PBS supplemented with 1% penicillin-streptomicin and 0.1% collagenase type I prewarmed to 37°C. The tissue was placed in a shaking water bath at 37°C with continuous agitation for 60 min and centrifuged for 5 min at 300 -500 g at room temperature. The supernatant, containing mature adipocytes, was recollected. The pellet was identified as the SVF. Isolated mature adipocytes and SVF were stored at Ϫ80°C for gene expression analysis.
Human adipocyte differentiation. Isolated human preadipocytes from SAT obtained from normal-weight (BMI Ͻ25) nondiabetic patients (Zen-Bio, Research Triangle Park, NC) were cultured and differentiated as described previously (10) . Cells were harvested and stored at Ϫ80°C for RNA extraction on days 0, 2, 5, 7, 9, 12, and 14. Mouse cell line 3T3-L1 differentiation. The embryonic fibroblast mouse cell line 3T3-L1 (American Type Culture Collection) was cultured and differentiated as described previously (10) . Mouse cell line 3T3-L1 was maintained in DMEM containing 20 mM glucose, 10% calf bovine serum, 100 U/ml penicillin, and 100 g/ml streptomycin. During 3T3-L1 adipocyte differentiation, calf bovine serum was changed into fetal bovine serum. Two days after confluence, an insulin (5 g/ml), dexamethasone (0.5 M), and isobutylmethylxanthine (0.5 mM) mixture was added for 2 days, followed by 5 days with insulin (5 g/ml) alone, which was replaced on day 5. Cells were then considered mature adipocytes. Cells were harvested and collected on days 0, 1, 2, 3, 4, 5, 6 , and 7 and stored at Ϫ80°C for RNA and protein extraction. Suboptimal adipocyte differentiation conditions were performed without insulin addition during the whole process and with the use of only dexamethasone (0.25 M) and isobutylmethylxanthine (0.25 mM) mixture for the first 2 days. Conditions of enhanced adipocyte differentiation were achieved by adding rosiglitazone (0.5 M) to the insulin (5 g/ml), dexamethasone (0.5 M), and isobutylmethylxanthine (0.5 mM) mixture for the first 2 days.
Intracellular lipid accumulation was measured by Oil Red O staining. For Oil Red O staining, cells were washed twice with PBS, fixed in 4% formaldehyde for 1 h, and stained for 30 min with 0.2% Oil Red O solution in 60% isopropanol. Cells were then washed several times with water, and excess water was evaporated by placing the stained cultures at ϳ32°C. To determine the extent of adipose conversion, 0.2 ml of isopropanol was added to the stained culture dish. The extracted dye was immediately removed by gentle pipeting, and its optical density was monitored spectrophotometrically at 500 nm using a multiwell plate reader (Model Anthos Labtec 2010 1.7 reader). Secreted adiponectin concentration in adipocyte-conditioned media during adipocyte differentiation was measured using a Mouse Adiponectin ELISA kit (EMA2500-1; Assaypro). Short-hairpin RNA-mediated knockdown of Dbc1. Permanent silencing was performed using Dbc1-targeted and control shRNA lentiviral particles (sc-108805-v and sc-108080; Santa Cruz Biotechnology, Santaz Cruz, CA), following the manufacturer's instructions.
Positive 3T3-L1 preadipocytes harboring short-hairpin (sh)RNA cassette for Dbc1 were selected by puromycin (3 g/ml) selection 60 h after infection. These experiments were performed two times starting with two independent pools of puromycin-selected cells, with three independent experiments for each pool. Dbc1-targeted and control shRNA lentiviral transfected cells of identical passage levels were studied and cultured in parallel.
RNA purification and gene expression. RNA was prepared from these samples using an RNeasy Lipid Tissue Mini Kit (Qiagen, Izasa, Gene expression was assessed by real-time PCR using a LightCycler 480 Real-Time PCR System (Roche Diagnostics, Barcelona, Spain), using TaqMan and SYBR green technology suitable for relative genetic expression quantification. The RT-PCR reaction was performed in a final volume of 12 l. The cycle program consisted of an initial denaturing of 10 min at 95°C and then 40 cycles of a 15-s denaturizing phase at 95°C and a 1-min annealing and extension phase at 60°C. A threshold cycle (C T value) was obtained for each amplification curve, and a ⌬CT value was first calculated by subtracting the CT value for human cyclophilin A (PPIA) RNA from the CT value for each sample. Fold changes compared with the endogenous control were then determined by calculating 2 Ϫ⌬CT , so gene expression results are expressed as expression ratio relative to PPIA gene expression according to the manufacturer's guidelines. Peptidylprolyl isomerase A (cyclophilin A) (PPIA) for human samples and cells and actin and EUK 18 rRNA for 3T3-L1 experiments were used as housekeeping. In human adipose tissue, the selection of PPIA as an endogenous control was supported by our previous experience (10) and other methodological studies (11) . In fact, in comparing PPIA, ACTB, GAPDH, or 18s gene expressions, PPIA was identified as the most stable mRNA in SAT and VAT samples in participants with different degrees of obesity. The commercially available and prevalidated TaqMan primer/ probe and SYBR green primer sets used are detailed in Table 1 .
Protein preparation. Proteins were extracted from adipose tissue and adipocytes by using a Polytron PT-1200C homogenizer (Kinematica, Lucerne, Switzerland) directly in radioimmnunoprecipitation assay (RIPA) buffer (0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, and 50 mM Tris·HCl, pH 8.0) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride). Cellular debris and lipids were eliminated by centrifugation of the solubilized samples at 13,000 rpm for 60 min at 4°C, recovering the soluble fraction below the fat supernatant and avoiding the nonhomogenized material at the bottom of the centrifuge tube. Protein concentration was determined using the RC/DC Protein Assay (BioRad Laboratories, Hercules, CA).
Western blot analysis. RIPA protein extracts (25 g) were separated by SDS-PAGE and transferred to nitrocellulose membranes by conventional procedures. Membranes were immunoblotted with anti-DBC1, anti-FAS, and anti-␤-actin (sc-166733, sc-20140, and sc-47778; Santa Cruz Biotechnology). Anti-rabbit IgG and anti-mouse IgG coupled to horseradish peroxidase were used as secondary antibodies. Horseradish peroxidase activity was detected by chemiluminescence, and quantification of protein expression was performed using scion image software from the same area for all analyzed bands.
Analytical methods. Serum glucose concentrations were measured in duplicate by the glucose oxidase method using a Beckman glucose analyzer II (Beckman Instruments, Brea, CA). Homeostasis model assessment (HOMA) was calculated using the following formula: [insulin (mU/l) ϫ glucose (mmol/l)]/22.5.
Statistical analyses. Statistical analyses were performed using SPSS 12.0 software. Unless stated otherwise, descriptive results of continuous variables are expressed as means Ϯ SD for Gaussian variables or median and interquartile range. Parameters that did not fulfill normal distribution were mathematically transformed to improve symmetry for subsequent analyses. The relation between variables was analyzed by simple correlation (Pearson's test and Spearman's test) and multiple regression analyses in a stepwise manner. One-factor ANOVA with post hoc Bonferroni test, paired t-test, and unpaired t-test was used to compare DBC1 gene expression according to obesity and type 2 diabetes. Nonparametric test (Mann-Whitney test) was used to analyze in vitro experiments. Levels of statistical significance were set at P Ͻ 0.05. For a given value of P ϭ 0.05, the study had a 98% power to detect significant correlations between DBC1 gene expression and metabolic parameters.
RESULTS
DBC1 gene expression in human adipose tissue. DBC1
gene expression was detected at substantial levels in both VAT and SAT in the two independent cohorts. In adipose tissue fractions, DBC1 gene expression was significantly more abundant in the adipocyte fraction compared with SVF (Fig. 1A) .
Anthropometric and metabolic parameters from cohort 1 are shown in table 2. DBC1 gene expression was equally decreased in obese and obese with type 2 diabetes when compared with nonobese participants (Table 2) . Previous studies have demonstrated that most of these genes were significantly decreased in association with obesity (12, 14) . For this reason, multiple regression analyses were performed. In VAT, PPAR␥ (␤ ϭ 0.53, P Ͻ 0.0001), GLUT4 (␤ ϭ 0.29, P ϭ 0.02), PLIN1 (␤ ϭ 0.53, P Ͻ 0.0001), FSP27 (␤ ϭ 0.26, P ϭ 0.03), ADRP (␤ ϭ 0.31, P ϭ 0.01), TIP47 (␤ ϭ 0.52, P Ͻ 0.0001), and ADIPOQ (␤ ϭ Ϫ0.31, P ϭ 0.01) contributed independently to DBC1 gene expression variance after controlling for BMI. In SAT, PPAR␥ (␤ ϭ 0.54, P Ͻ 0.0001), TIP47 (␤ ϭ 0.30, P ϭ 0.01), and PRKACA (␤ ϭ 0.38, P ϭ 0.003) contributed independently to DBC1 gene expression variance after controlling for BMI. Also in SAT, DBC1 was inversely associated with HOMA-IR, but this association was lost after adjusting for BMI.
We confirmed some of these associations in a second independent cohort composed of morbidly obese subjects aged Similarly to cohort 1, both VAT and SAT DBC1 mRNA levels were positively associated with GLUT4, PLIN1, and FSP27 gene expression (Table 4) . Moreover, DBC1 mRNA levels were also positively associated with ADRP and TIP47 gene expression in VAT and with PRKACA gene expression in SAT (Table 4) .
In a subgroup of 10 subcutaneous adipose tissue (SAT) samples, DBC1 protein levels were significantly correlated with DBC1 mRNA levels (r ϭ 0.71, P ϭ 0.016; Fig. 1B) .
DBC1 mRNA and protein levels during human and 3T3-L1 adipocyte differentiation. DBC1 gene expression increased in the early stages of subcutaneous and visceral adipocyte differentiation, showing the maximum levels on day 7, and then decreased slightly at the end of this process (Fig. 1C) . In 3T3-L1 cells, Dbc1 mRNA and protein levels also increased in the early stages of adipocyte differentiation and remained increased at the end of this process (Fig. 2) . Effects of Dbc1 knockdown on 3T3-L1 adipogenesis. To investigate the possible role of DBC1 on adipocyte differentiation, we performed functional knockdown of the DBC1 gene in 3T3-L1 preadipocytes (Fig. 3A) . Interestingly, Dbc1 knockdown (KD; Ϫ55%) led to enhanced adipocyte differentiation, increased intracellular lipid accumulation (Fig.  3B) , and expression of adipogenic (50%; Fig. 3C ) and lipogenic (25%; Fig. 3D ) genes, which was confirmed at the protein level [for FAS (Fig. 3E ) and secreted adiponectin concentration (Fig. 3F)] . Otherwise, no significant effects were found in lipolytic gene expression (Fig. 3G) . The adipogenic effect of Dbc1 KD was observed at different points (days 2 and 7) of adipocyte differentiation process, even under suboptimal conditions (Fig. 4A) and conditions of enhanced adipocyte differentiation (Fig. 4B) . Even though genetic deletion of Dbc1 in mice led to enhanced browning of white adipose tissue (13), gene expression of Ucp1 was detected at very low levels (C T Ͼ 36) in Dbc1 KD cells, similar to control cells.
DISCUSSION
The main finding of this study was that DBC1 mRNA was detected at relatively abundant levels in human adipose tissue (in both VAT and SAT). To the best of our knowledge, this is the first study evaluating the possible role of DBC1 in human adipose. DBC1 mRNA was higher in adipocytes when compared with SVF.
The expression of DBC1 was significantly decreased in adipose tissue from obese subjects. DBC1 mRNA was concordantly detected in inverse proportion to ADIPOQ (in both univariate and multivariate analyses). Because decreased ADIPOQ gene expression is known to be present with adipocyte hypertrophy and adipose tissue dysfunction (7), DBC1 mRNA could also constitute a marker of adipose tissue functionality and adipogenesis. In fact, DBC1 mRNA was also detected in direct proportion to different lipid droplet-and lipolytic-associated genes in the two cohorts of subjects studied. It is well known that expression of lipo- genic and lipolytic genes is reduced in obese subjects (12, 14) . The associations of DBC1 mRNA with lipid dropletassociated and lipolytic genes and GLUT4 persisted even after adjusting for BMI. Interestingly, a significant association between DBC1 and SIRT1 mRNA levels was found in both SAT and VAT across a wide spectrum of adiposity (cohort 1) but not within morbidly obese subjects (cohort 2). Sirtuin activity is known to attenuate high-fat diet-induced adipose tissue inflammation (6, 16) , whereas other studies have shown that DBC1 induces adipocyte senescence and inflammation (5) . In fact, high-fat diet-induced obesity is known to decrease sirtuin activity through DBC1-SIRT1 protein interaction in adipose tissue (4, 17) . DBC1 might also attenuate sirtuin activity in human adipose tissue during the development of obesity, resulting in adipose tissue dysfunction.
DBC1 mRNA and protein levels increased in the early stages of adipocyte differentiation in both human and 3T3-L1 adipocytes. To the best of our knowledge, this is the first study evaluating DBC1 during differentiation of these cells.
Strikingly, DBC1 was positively correlated with PPAR␥ gene expression in both fat depots. Since PPAR␥ is the master regulator of adipogenesis, a possible role of DBC1 in this process is suggested. In fact, DBC1 gene expression was higher in adipocytes vs. SVF and increased in the early stages of adipocyte differentiation. However, the expression pattern of DBC1 was slightly different from that of adipogenic genes (ADIPOQ and FASN), indicating that DBC1 and PPAR␥-dependent adipogenesis belong to separate pathways.
Dbc1 knockdown resulted in enhanced adipogenesis. These functional in vitro experiments disclosed that Dbc1 knockdown resulted in increased expression of adipogenic genes in parallel with intracellular lipid accumulation, suggesting an inhibitory role of DBC1 on adipogenesis. In agreement with this finding, DBC1-KO mice displayed a "healthy" obese phenotype, were significantly more obese than wild-types, and were protected against high-fat diet-induced adipose tissue dysfunction (4). DBC1 deletion led to not only increased adipose tissue and adipocyte storage capacity but also increased insulin action in parallel with downregulation of inflammatory mRNAs (4). Here, we describe similar observations after DBC1 knockdown. In DBC1-KO mice, no significant differences in lipolysis markers in adipose tissue were found (4). In agreement with this, lipolytic genes mRNA did not change significantly after DBC1 knockdown (current observations).
Importantly, the significant increase in adipogenic gene expression, secreted adiponectin concentration, and intracellular Oil Red O accumulation in nontreated vs. lentiviral-transfected 3T3-L1 cells suggest that viral infection, drug selection, and the extended number of passages attenuated adipocyte differentiation in lentiviral-transfected 3T3-L1 cells. The low level of adipogenesis in these cells constitutes a significant limitation of this study. To address this limitation, the effects of Dbc1 knockdown on adipocyte differentiation were tested under suboptimal conditions and conditions of enhanced adipocyte differentiation. Remarkably, the expression of several adipogenic genes was increased significantly in Dbc1 knockdown cells in both situations.
In conclusion, although DBC1 gene expression was reduced in adipose tissue from obese subjects, it was negatively associated with ADIPOQ gene expression in VAT, suggesting that DBC1 might promote VAT dysfunction. In vitro data support the antiadipogenic effects of DBC1.
